Pharmacological management of acutely agitated schizophrenic patients

Current Pharmaceutical Design

Volumn 11, Issue 19, 2005, Pages 2471-2477

  San, L ^a   Arranz, B ^b   Escobar, R ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^c ELI LILLY AND COMPANY   (Spain)

Author keywords

Agitation; Atypical antipsychotics; Intramuscular; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUNITRAZEPAM; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

AKATHISIA; AKINESIA; CAREGIVER; CLINICAL TRIAL; COGNITIVE DEFECT; DELIRIUM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE NEED; HUMAN; INDIVIDUALIZATION; MEDICAL DECISION MAKING; META ANALYSIS; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PATIENT CARE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SOMNOLENCE; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA;

EID: 21044449292     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054367472     Document Type: Review

References (49)

1. Humphreys MS, Johnstone EC, Mae Millan JF, Taylor PJ. Dangerous behavior preceding first admission for schizophrenia. Br J Psychiatry 1992; 161: 501.
2. Beaudoin MN, Hodgins S, Lavoie F. Homicide, schizophrenia and substance abuse and dependency. Can J Psychiatry 1993; 38: 541.
3. Virkkunen M. Observations on violence in schizophrenia. Acta Psychiatr Scand 1974; 50: 145.
4. Citrome L, Volavka J. Psychiatric disorders and violence. In: Medical management of the violent patient. Clinical assessment and therapy. Ed. Kenneth Tardiff, New York. Marcel Dekker, Inc 1999; 125-152.
5. Pilowsky LS, Ring H, Shine PJ, Battersby M, Lader M. Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. Br J Psychiatry 1992; 160: 831-835.
6. Kunik ME, Yudofsky SC, Silver JM, Hales RE. Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994; 55 (Suppl): 13-17.
7. Yudofsky SC, Silver JM, Hales RE. Treatment of Agitation and Aggression. In: The American Psychiatric Press Textbook of Pscychopharmacology. Eds: Schaltzberg AF, Nemeroff CB; Washington DC, American Psychiatric Press, 1998; 881-900.
8. Hughes DH. Acute psychopharmacological management of the aggressive psychotic patient. Psychiatr Serv 1999; 50: 1135-1137.
9. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med Special Report 2001;1-88.
10. Feifel D. Psychopharmacology in the acute setting: review and proposed guidelines. Psychiatric Times 2001; 17(5):1-6.
11. Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry 1990; 51(suppl 5): 41-46.
12. Lerner Y, Lwow E, Levitan A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 1979; 136: 1061-1064.
13. Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg 1997; 15(4): 335-340.
14. Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12(3): 175-179.
15. Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52(4): 177-180.
16. Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999; 156: 142-144.
17. Davis PJ, Cook DR. Clinical pharmacokinetics of the new intravenous anesthetic agents. Clin Pharmacokinet 1986; 11: 18-35.
18. Hoey LL, Nahum A, Vance-Bryan K. A retrospective review and assessment of benzodiazepines in the treatment of alcohol withdrawal in hospitalized patients. Pharmacotherapy 1994; 14: 572-578.
19. Mattila MAK, Larni HM. Flunitrazepam: a review of is pharmacological properties and therapeutic use. Drugs 1980; 20: 353-374.
20. Wickstrom E, Amrein R, Haefefinger P, Hartman D. Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. Eur J Clin Pharmacol 1980; 17: 189-196.
21. Allen MH. Managing the agitated psychotic patient. A reappraisal of the evidence. J Clin Psychiatry 2000; 61 (suppl 14): 11-20.
22. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc inverval, torsade de points, and sudden death. Am J Psychiatry 2001; 158: 1774-1782.
23. Salzman C, Green AI, Rodríguez-Villa F, Jaskiw GI. Benzodiazepines combined with neuroleptics for management of severe diruptive behavior. Psychosomatics 1986; 27 (1 suppl): 17-22.
24. Bieniek SA, Ownby RL, Penalver A, Dominguez RA. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998; 18(1): 57-62.
25. Currier GW. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000; 61 (suppl 14): 21-26.
26. Karagianis JL, Dawe IC, Thakur A, Begin S, Raskin J, Roychowdhury SM. Rapid tranquilization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001;62(suppl 2): 12-16.
27. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics. Uses and relevance in clinical practice. Drugs 2003; 63(5): 493-512.
28. Aleman A, Kahn RS. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol 2001; 11: 289-293.
29. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62: 153-157.
30. Currier GW, Chou JCY, Feifel D, Bossie CA, Mahmoud RA, Gharabawi GM. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65:386-394.
31. Lesem MD, Zajecka JM, Swift RH, Roeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62: 12-18. Correction 2001; 62: 209.
32. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155(2): 128-134.
33. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61: 933-941.
34. Pfizer Inc. Data on file. New York: Pfizer Inc.
35. Geodon [package insert]. New York: Pfizer Inc, 2002.
36. Goodnick PJ. Ziprasidone: profile (in safety. Expert Opin Pharmacother 2001; 2: 165 5-1662.
37. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Therapeutics 2002; 24(1): 21-37.
38. Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001; 62 (suppl 2): 17-21.
39. Bergstrom R, Mitchell M, Jewell H, Richards J, McEwan J, Hatcher B. Examination of the safety, tolerance and pharmacokinetics of intramuscular (IM) olanzapine compared to oral olanzapine in healthy subjects. Schizophr Res 1999; 36: 305-306.
40. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149-1151.
41. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441-448.
42. Lindborg SR, Beasley CM, Alaka K, Taylor CC. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003; 119: 113-123.
43. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23: 342-348.
44. Guthrie SK. Managing psychiatric drug therapy across the continuum of care: focus on the schizophrenic patient. Am J Health-Sys Pharm 2002; 59 (Suppl 5): S3-S4.
45. Feifel D. Rationale and guidelines for the inpatient treatment of acute psychosis. J Clin Psychiatry 2000; 61 (suppl 14): 27-32.
46. McAllister-Williams RH, Ferrier IN. Rapid tranquil isation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002; 180: 485-489.
47. Hughes DH, Kleespies PM. Treating aggression in the psychiatric emergency service. J Clin Psychiatry 2003; 64 (Suppl 4): 10-15.
48. Humble F, Berk M. Pharmacological management of aggression and violence. Hum Psychopharmacol Clin Exp 2003; 18: 423-436.
49. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med 3 2003; 20: 339-346.